Pharmacologic management of Alzheimer's disease

Clinics in Geriatric Medicine

Volumn 14, Issue 1, 1998, Pages 129-146

  Kumar, V ^a   Durai, U N B ^a   Jobe, T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DESIPRAMINE; DONEPEZIL; ESTROGEN; FLUOXETINE; LITHIUM; MUSCARINIC AGENT; NEFAZODONE; NEUROLEPTIC AGENT; NICOTINIC AGENT; NORTRIPTYLINE; PAROXETINE; PHOSPHATIDYLCHOLINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

AGED; AGITATION; ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; BONE MARROW TOXICITY; BRAIN PROTECTION; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LIVER TOXICITY; NEUROTOXICITY; PSYCHOSIS; REVIEW; STEVENS JOHNSON SYNDROME;

EID: 0031911166     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0749-0690(18)30134-4     Document Type: Review

References (67)

1. American Psychiatric Association: Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life Am J Psychiatry 154 5 1997 20 26
2. R. Anand Presented at the International Psychogeriatric Meeting Clinical experience with cholinesterase inhibitors in Alzheimer’s disease 1997 Jerusalem Israel, August
3. R. Anand Efficacy and safety result of the early phase studies with Exelon (ENA-173) in Alzheimer’s Disease: An overview J Drug Dev Clin Pract 8 2 1996 1 8
4. S.J. Birge Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 44 1996 865 870
5. J.C.S. Breitner B.A. Lau K.A. Welsh Inverse association of anti-inflammatory treatments and Alzheimer’s disease: Initial results of a co-twin control study Neurology 44 1994 227 232
6. C.A. Chambers J. Bain R. Rosbottom Carbamazepine in senile dementia and overactivity: A placebo-controlled double blind trial IACS Med Sci 10 1982 505 506
7. G. Chattellier L. Lacomblez Tacrine (tetrahydroamnioacridine; THA) and lecithin in senile dementia of the Alzheimer’s type: A multicenter trial Br Med J 300 1990 495 499
8. J. Cohen-Mansfield M.S. Marx A.S. Rosenthal A description of agitation in a nursing home J Gerontol 44 1989 m77 m84
9. P.J. Cowen Advances in psychopharmacology: Mood disorders and dementia Br Med Bull 52 3 1996 539 555
10. F. Elliott Propranolol for the control of belligerent behavior following acute brain damage Ann Neurol 1 1997 489 491
11. H. Fillit H. Weinreb I. Cholst Observations in a preliminary open trial of estradiol therapy for senile dementia (Alzheimer’s type) Psychoneuroendocrinology 2 1986 337 345
12. W. Fischer Amelioration of cholinergic neuro atrophy and spatial memory impairment in aged rats by nerve growth factor Nature 329 6134 1987 38 65
13. A. Fuchs U. Henke D.H. Erhart Video rating analysis of effect of maprotiline in patients with dementia and depression Pharmacopsychiatry 26 1992 37 41
14. S. Gautheir Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease N Engl J Med 322 1988 1272 1276
15. E. Giacobini Pharmacotherapy of Alzheimer’s disease: New drugs and novel strategies Prog Brain Res 98 1993 447 454
16. R.M. Greendyke D.R. Kanter Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study J Clin Psychiatry 47 8 1986 423 426
17. J.H. Growdon Treatment for Alzheimer’s disease N Engl J Med Vol327 18 1992 1306 1308
18. R. Hellweg Nerve growth factor levels and choline acetyltransferase activity in the brains of aged rats with spatial memory impairment Brain Res 537 1990 123 130 1–2
19. H. Honjo Y. Ogino K. Naitoh In vivo effects by estrogen sulfate in the central nervous system–senile dementia (Alzheimer’s type) J Steroid Biochem 34 1989 521 525
20. H. Honjo Y. Ogino M. Tanaka An effect of conjugated estrogen to cognitive impairment in women with senile dementia–Alzheimer’s type: A placebo-controlled double blind study J Jpn Menopause Soc. 1 1993 167 171
21. W.H. Kay Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment Biol Psychiatry 17 1982 275 280
22. Kennedy JS, Kwentus JA, Kumar V: Cholinergic system therapy for Alzheimer’s disease In Kumar V, Eisdorfer C: Advances in diagnosis and treatment of Alzheimer’s disease New York Springer, in press
23. K.R.R. Krishnan D.C. Steffans M. Doraiswany Psychotropic drug interactions Primary Psychiatry 3 1 1996 21 49
24. L.H. Kuller Hormone replacement therapy and its potential relationship to dementia J Am Geriatr Soc 44 1996 878 880
25. V. Kumar Antioxidants clinical trial for Alzheimer’s disease 1997 International Conference on Antioxidants and Neurodegenerative Disorder Chicago
26. V. Kumar Use of atypical antipsychotic agents in geriatric patients: A review Int J Geriatric Psychopharmacol 1 1997 15 23
27. V. Kumar K. Sugaya S. Saunder Update on cholinergic drugs in Alzheimer’s disease Drug Research 32 7 1996 529 537
28. V. Kumar E. Giacobini New Research, Annual Meeting of American Psychiatric Association, May Heterogeneity of Alzheimer’s disease: Biological and clinical correlates 1988 Montreal Canada
29. V. Kumar Cholinergic drugs in Alzheimer’s disease: Past, present, future M. Bergener S.I. Finkel Treating Alzheimer’s and Other Dementias 484 1995 Springer New York 495
30. J.T. Lake G.T. Grossberg Management of psychosis, agitation, and other behavioral problems in Alzheimer’s disease Psychiatric Ann 17 1987 371 374
31. B.A. Lawler J. Radcliffe S.E. Molchan A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease Int J Geriatr Psychiatry 9 1994 55 59
32. D.M.A. Mann N. Yuonis D. Jones The timeline of pathological events in Down’s syndrome with particular reference to the involvement of microglial cells and deposits of ß/A4 Neurodegeneration 1 1992 201 215
33. J. Marx Searching for drugs that combat Alzheimer’s Science 273 1996 50 53
34. P.L. McGeer N. Harada H. Kimuva Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy Dementia 3 1992 146 149
35. P.L. McGeer E. Mehee J. Rogers Anti-inflammatory drugs and Alzheimer’s disease Lancet 335 1990 1037
36. J.C. Monfort The difficult elderly patient: Curable hostile depression or personality disorder? Int Psychogeriatr 7 1995 95 111
37. M. Narayan J.C. Nelson Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic J Clin Psychiatry 58 8 1997 351 354
38. R.M. Nitsch R.J. Wurtman J.H. Growdon Regulation of APP processing potential for the therapeutical reduction of brain amyloid burden Ann NY 777 1996 175 182
39. A.L. Nyth C.G. Gottfries The clinical efficacy of citolopram in treatment of emotional disturbances in dementia disorders: A nordic multicenter study Br J Psychiatry 157 1996 894 901
40. A.L. Nyth C.G. Gottfries K. Lyby A controlled multicenter clinical study of Citalopram and placebo in elderly depressed patients with and without concomitant dementia Acta Psychiatr Scand 86 1992 138 145
41. T. Ohkura K. Isse K. Akagawa Evaluation of estrogen treatment in female patients with dementia of the Alzheimer’s type Endocrine J 41 1994 361 371
42. T. Ohkura K. Isse K. Akazawa Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer’s type: Seven case reports Dementia 6 1995 99 107
43. C. Peisah H. Brodaty Practical guidelines for the treatment of behavioral complications of dementia Med J Aust 161 1994 558 563
44. B.H. Peters H. Levin Effects of physostigmine and lecithin on memory in Alzheimer’s disease Ann Neurol 6 1979 219 221
45. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life Am J Psychiatry 154 5 1997 20 25
46. P.G. Janicak J.M. Davis S.H. Preskorn Principles and Practice of Psychopharmacotherapy 1993 Williams & Wilkins Baltimore 230 231
47. B.V. Reifler L. Teri M. Raskind Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression Am J Psychiatry 146 1989 45 49
48. N.K. Robakis J.P. Anderson L.M. Refolo Expression of the Alzheimer’s amyloid precursor in brain tissue and effects of NGF and EGF on its metabolism Clin Neuropharmacol 14 1991 S15 S23
49. J. Rogers L.C. Kirby S.R. Hempelman Clinical trial of indomethacin in Alzheimer’s disease Neurology 43 1993 1609 1611
50. K. Sakauye C. Camp P. Ford Effects of buspirone on agitation associated with dementia Am J Geriatric Psychiatry 1 1993 82 84
51. M. Sano C. Ernesto R.G. Thomas A controlled trial of seligiline, alpha-tocopherol or both as treatment for Alzheimer’s disease N Engl J Med 336 17 1997 1216 1222
52. D.B. Schenk R.E. Rydel P. May Therapeutic approaches related to amyloid-ß peptide and Alzheimer’s disease J Med Chem 38 21 1995 4141 4154
53. L.S. Schneider V.E. Pollock S.A. Lyness A metaanalysis of controlled trials of neuroleptic treatment of dementia J Am Geriatr Soc 38 1990 553 563
54. A. Seiger Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy Behav Brain Res 57 2 1995 255 261
55. P.M. Simpson D. Foster Improvement in organically disturbed behavior with trazodone treatment J Clin Psychiatry 47 1986 191 193
56. N.R. Smalheiser D.R. Swanson Indomethacin and Alzheimer’s disease Neurology 46 2 1996 583
57. K. Sugaya Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer’s disease J Neurosci Res 27 3 1990 349 359
58. P.N. Tariot R. Erb A. Leibovici Carbamazepine treatment of agitation in nursing home patients with dementia a preliminary study J Am Geriatr Soc 42 1994 1160 1166
59. L.J. Thal Acute and chronic effects of oral physostigmine and lecithin in Alzheimer’s disease Prog Neuropsychopharmacol Biol Psychiatry 10 1986 627 636
60. T. Tomiyama A. Shoji K. Kataoka Inhibition of amyloid-ß protein aggregation and neurotoxicity by Rifampicin J Biol Chem 271 12 1996 6839 6844
61. M.J. Tueth Dementia: Diagnosis and emergency behavioral complication J Emerg Med 13 4 1995 519 525
62. A. Wettstein No effect from double-blind trial of physostigmine and lecithin in Alzheimer’s disease Arch Neurol 13 1983 210 212
63. P.J. Whitehouse Nicotinic acetylcholine binding sites in Alzheimer’s disease Brain Res 371 1 1986 146 151
64. R.E. Wragg D.V. Jeste Overview of depression and psychosis in Alzheimer’s disease Am J Psychiatry 146 1989 577 587
65. R.S. Wurtman Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer’s disease Neurochem Int 7 1985 369 375
66. B.F. Yeager L.E. Farnett S.A. Ruzicka Management of the behavioral manifestations of dementia Arch Intern Med 155 1995 250 260
67. S. Yudofsky Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndrome Am J Psychiatry 138 1981 218 230